Background: Tripterygium glycosides (TG) has been used to treat a spectrum of inflammatory and autoimmune diseases. Our preliminary studies have shown that TG is effective in the treatment of active Graves' ophthalmopathy (GO).
Objective: We aimed to compare the efficacy and tolerability of TG with intravenous methylprednisolone (iv.MP) in patients with active moderate-to-severe GO.
Methods: This study was an observer-masked, single-centre, block-randomised trial. Patients with active moderate-to-severe GO were randomly assigned to receive iv.MP (500 mg once per week for 6 weeks followed by 250 mg per week for 6 weeks) or with TG (20 mg tablet three times per day for 24 weeks). The primary endpoints were the overall response rate and the patients' quality of life at 12 and 24 weeks.
Results: In this study, 161 patients were enrolled and randomised from 2015 to 2019. A total of 79 were randomly assigned to receive iv.MP and 82 to receive TG. A greater overall response rate was found in the TG group compared with the iv.MP group at week 24 (90.2% vs 68.4%, P = 0.000). Similarly, the patients' quality of life of the TG group showed a significantly higher response than the iv.MP group at week 24 (89.02% vs 72.15%, P = 0.001). The TG therapy showed a better CAS response than the iv.MP (91.5% vs 70.9% improved, P < 0.05), and up to 91.2% of patients were inactive. Also, the TG group showed a significantly higher improved rate of diplopia, proptosis, visual acuity, soft tissue involved and the decrease of eye muscle motility than the iv.MP group at week 24. Significantly more patients in the iv.MP group than the TG group experienced adverse events.
Conclusion: Compared with iv.MP treatment, TG therapy is more effective and safer for patients with active moderate to severe GO.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849376 | PMC |
| http://dx.doi.org/10.1530/EJE-20-0857 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical efficacy of efgartigimod combined with intravenous methylprednisolone in the acute phase of neuromyelitis optica spectrum disorders.
Orphanet J Rare Dis
December 2024
Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, No. 58 Zhongshan Road 2, Guangzhou, 510080, China.
Background: Neuromyelitis Optica Spectrum Disorders (NMOSD) comprise a group of autoimmune-mediated, inflammatory, demyelinating central nervous system diseases caused by aquaporin-4 (AQP4) IgG autoantibodies. Efgartigimod is a human IgG Fc fragment that reduces antibody titers by targeting the neonatal Fc receptor (FcRn). This study documents the efficacy of efgartigimod combined with intravenous methylprednisolone (IVMP) in the acute phase of NMOSD.
View Article and Find Full Text PDFBTK and YKL-40 Levels and Their Association with Acute AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Mol Neurobiol
November 2024
Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China.
Article Synopsis
- This study explored the relationship between BTK/YKL-40 levels and the severity of AQP4-IgG + NMOSD, aiming to find biomarkers that could be useful for monitoring the disease and assessing treatment.
- Plasma YKL-40 levels in acute-phase NMOSD patients before treatment were notably higher compared to those after treatment, in remission, or in healthy individuals, indicating its role in disease severity.
- The research found strong correlations between elevated YKL-40, BTK, and NF-κB levels with increased disability scores, suggesting these biomarkers could predict disease activity and treatment response in NMOSD patients.
New diagnosis of multiple sclerosis in the setting of recent Sinopharm COVID-19 vaccine (BBIBP-CorV) exposure: A series of clinical cases and updated review of the literature.
Curr J Neurol
January 2024
Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Multiple sclerosis (MS) is a leading cause of non-traumatic disability in young people, and there are few cases reported of demyelinating events after COVID-19 vaccination.
- In a study, 8 out of 338 newly diagnosed MS patients experienced their first symptoms within 6 weeks post-Sinopharm vaccine, with an average onset of 2 weeks.
- All patients were found to have demyelinating lesions on MRI and were treated with medications like intravenous steroids and Rituximab; however, more comprehensive studies are necessary to better understand the relationship between the vaccine and MS onset.
Effect of intravenous methylprednisolone on serum antibody levels in thyroid eye disease.
Br J Ophthalmol
September 2024
Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (the Republic of)
Article Synopsis
- The study assessed changes in autoantibodies in patients with thyroid eye disease undergoing intravenous methylprednisolone (IVMP) treatment over 12 months, comparing them with untreated patients.* -
- Results indicated that IVMP led to a rapid decrease in TSH receptor antibody levels for the first six months, but by the end of the study, levels were similar in both treated and untreated groups.* -
- High total cholesterol levels were identified as a significant prognostic factor affecting the response to IVMP, with a threshold of 186 mg/dL distinguishing between effective and ineffective treatment responses.*
The use of intravenous methylprednisolone in giant cell arteritis-a population-based study.
Rheumatology (Oxford)
August 2024
Department of Clinical Sciences, Rheumatology, Lund University, Sweden, Lund.
Objectives: To determine clinical characteristics, outcome, and occurrence of comorbidities in patients with biopsy-confirmed giant cell arteritis (GCA) treated with intravenous methylprednisolone (IVMP) vs those receiving oral glucocorticoids (OGC) only.
Methods: A retrospective study included patients with GCA diagnosed from 2004 through 2019. Clinical and laboratory characteristics, and cumulative GC dose were compared in patients receiving IVMP vs OGCs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!